← FDA DRUG APPROVALS

FDA ANDA · ANDA209314

POTASSIUM CHLORIDE

Sponsor: YICHANG HUMANWELL

APPLICATION
ANDA209314
TYPE
ANDA
ORIGINAL APPROVAL
2018-06-22
LATEST ACTION
2018-06-22
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

POTASSIUM CHLORIDEPrescription
POTASSIUM CHLORIDE 8MEQ · TABLET, EXTENDED RELEASE · ORAL
POTASSIUM CHLORIDEPrescription
POTASSIUM CHLORIDE 10MEQ · TABLET, EXTENDED RELEASE · ORAL

Approval history

2018-06-22UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →